Recent progress in treatment of anti-thyroid drugs on pregnant women with hyperthyroidism

doi:10.3969/j.issn.1004-583X.2016.03.006

Abstract

Abstract: Hyperthyroidism in pregnancy, especially overt hyperthyroidism can cause adverse pregnancy outcomes, including eclampsia, abortion, preterm birth,gestational diabetes and fetal intrauterine growth restriction, which is a serious threat to the mother and fetus' health. Anti-thyroid drug (ATD) is the first line of choice for those patients, but recent studies found methimazole and propylthiouracil have teratogenic effects. Moreover, they are possible to cause liver function failure and other serious adverse effects, but the degree is different. Therefore, it is very important to appropriately use ATD to protect the health of mother and fetus, especially to restrict the use in the first trimester of pregnancy (6-10 weeks).

Key words: atrialfibrillation, thromboembolism, percutaneousleftatrialappendagetranscatheterocclusion, hyperthyroidism, pregnancy, antithyroid agents

CLC Number:

R581.1

Li Hui,Li Jing. Recent progress in treatment of anti-thyroid drugs on pregnant women with hyperthyroidism[J]. Clinical Focus, 2016, 31(3): 254-257.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.03.006

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I3/254

References

[1] Nathan N, Sullivan SD.Thyroid disorders during pregnancy[J]. Endocrinol Metab Clin North Am,2014, 43(2):573-597.
[2] 滕卫平,段涛,宁光.妊娠和产后甲状腺疾病诊治指南[J].中华内分泌代谢杂志,2012,28(5): 356-356.
[3] Ajmani SN, Aggarwal D, Bhatia P, et al.Prevalence of overt and subclinical thyroid dysfunction among pregnant women and its effect on maternal and fetal outcome[J]. J Obstet Gynaecol India, 2014, 64(2): 105-110.
[4] Aggarawal N, Suri V, Singla R, et al.Pregnancy outcome in hyperthyroidism:a case control study[J]. Gynecol Obstet Invest,2014,77(2):94-99.
[5] Andersen SL, Laurberg P, Wu CS, et al.Attention deficit hyperactivity disorder and autism spectrum disorder in children born to mothers with thyroid dysfunction:a Danish nationwide cohort study[J].BJOG,2014,121(11): 1365-1374.
[6] Cooper DS, Laurberg P.Hyperthyroidism　in pregnancy[J]. Lancet Diabetes Endocrinol,2013,1(3):238-249.
[7] Lazarus JH. Management of hyperthyroidism in pregnancy[J].Endocrine, 2014,45(2):190-194.
[8] De Groot L, Abalovich M, Alexander EK, et al.Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline[J]. J Clin Endocrinol Meta, 2012, 97(8): 2543-2565.
[9] Sun S, Qiu X, Zhou J.Clinical analysis of 65 cases of hyperemesis gravidarum with gestational transient thyrotoxicosis[J]. J Obstet Gynaecol Res,2014,40(6): 1567-1572.
[10] Casey BM, Dashe JS, Wells CE, et al.Subclinical hyperthyroidism and pregnancy outcomes[J]. Obstet Gynecol, 2006, 107(2 Part 1): 337-341.
[11] Rubin PC.Current concepts: beta-blockers in pregnancy[J]. N Engl J Med, 1981,305(22):1323-1326.
[12] Cooper DS. Antithyroid drugs[J].N Engl J Med,2005,352(9):905-917.
[13] Clementi M, Di Gianantonio E, Cassina M, et al. Treatment of hyperthyroidism in pregnancy and birth defects[J].J Clin Endocrinol Metab,2010,95(11):E337-341.
[14] Cassina M, Dona M, Di Gianantonio E, et al.Pharmacologic treatment of hyperthyroidism during pregnancy[J]. Birth Defects Res A Clin Mol Teratol,2012,94(8): 612-619.
[15] Marchant B,Brownlie BE,Hart DM, et al.The placental transfer of propylthiouracil, methimazole and carbimazole[J]. J Clin Endocrinol Metab,1977, 45(6): 1187-1193.
[16] Mortimer RH, Cannell GR, Addison RS, et al. Methimazole and propylthiouracil equally cross the perfused human term placental lobule[J]. J Clin Endocrinol Metab,1997, 82(9):3099-3102.
[17] Andersen SL, Olsen J, Wu CS, et al. Severity of birth defects after propylthiouracil exposure in early pregnancy[J]. Thyroid, 2014, 24(10): 1533-1540.
[18] Laurberg P, Andersen SL. Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relativesafety and high risk [J]. Eur J Endocrinol, 2014, 171(1): R13-R20.
[19] Van Veenendaal NR, Ulmer B, Boskovski MT, et al.Embryonic exposure to propylthiouracil disrupts left-right patterning in Xenopus embryos[J]. FASEB J,2013, 27(2): 684-691.
[20] Yoshihara A, Noh JY, Yamaguchi T, et al.Treatment of Graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation[J]. J Clin Endocrinol Metab, 2012, 97(7): 2396-2403.
[21] Andersen SL, Olsen J, Wu CS, et al.Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study[J]. J Clin Endocrinol Metab ,2013, 98(11): 4373-4381.
[22] Heidari R, Niknahad H, Jamshidzadeh A, et al.Factors affecting drug-induced liver injury: antithyroid drugs as instances[J]. Clin Mol Hepatol,2014,20(3):237-248.
[23] Yang J, Li L, Xu Q, et al.Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China[J].Thyroid,2015,25(3): 278-283.
[24] Bahn RS, Burch HB, Cooper DS, et al.Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists[J].Thyroid, 2011,21(6):593-646.
[25] Carney LA, Quinlan JD, West JM.Thyroid disease in pregnancy[J]. Am Fam Physician, 2014, 89(4):273-278.
[26] Ferreira C,Costa T,Marques AV.Diffuse alveolar haemorrhage secondary to propylthiouracil-induced vasculitis[J]. BMJ Case Rep , 2015, Feb 6.
[27] Momotani N, Yoshimura Noh J,Ishikawa N, et al. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves’ hyperthyroidism[J]. J Clin Endocrinol Metab, 1997, 82(11): 3633-3636.